268 related articles for article (PubMed ID: 16357128)
1. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
Kambara H; Saeki Y; Chiocca EA
Cancer Res; 2005 Dec; 65(24):11255-8. PubMed ID: 16357128
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
3. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
4. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.
Friedman A; Tian JP; Fulci G; Chiocca EA; Wang J
Cancer Res; 2006 Feb; 66(4):2314-9. PubMed ID: 16489036
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
6. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses.
Li H; Zeng Z; Fu X; Zhang X
Cancer Res; 2007 Aug; 67(16):7850-5. PubMed ID: 17699791
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma.
Huszthy PC; Goplen D; Thorsen F; Immervoll H; Wang J; Gutermann A; Miletic H; Bjerkvig R
Clin Cancer Res; 2008 Mar; 14(5):1571-80. PubMed ID: 18316582
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
[TBL] [Abstract][Full Text] [Related]
10. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.
Wakimoto H; Johnson PR; Knipe DM; Chiocca EA
Gene Ther; 2003 Jun; 10(11):983-90. PubMed ID: 12756419
[TBL] [Abstract][Full Text] [Related]
11. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
12. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
[TBL] [Abstract][Full Text] [Related]
13. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
14. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
15. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
16. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
17. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
Griffith C; Noonan S; Lou E; Shillitoe EJ
Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
19. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
[TBL] [Abstract][Full Text] [Related]
20. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.
Advani SJ; Buckel L; Chen NG; Scanderbeg DJ; Geissinger U; Zhang Q; Yu YA; Aguilar RJ; Mundt AJ; Szalay AA
Clin Cancer Res; 2012 May; 18(9):2579-90. PubMed ID: 22379115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
